RT @HealthCoreRWE: We evaluated real-world treatment patterns associated with D-ER use. https://t.co/DUHqP1a3MT #multiplesclerosis

RT @HealthCoreRWE: We evaluated real-world budget impact associated with D-ER use. https://t.co/DUHqP1a3MT #multiplesclerosis

RT @HealthCoreRWE: We evaluated real-world healthcare resource utilization associated with D-ER use. https://t.co/DUHqP1a3MT #multiplescler…

RT @HealthCoreRWE: Patients who used D-ER had fewer trips to the doctor for walking-related issues. https://t.co/DUHqP1a3MT #multiplesclero…

RT @HealthCoreRWE: Our analysis is one of the 1st 2 eval D-ER treatment patterns, budget impact, & HRU of #multiplesclerosis patients. http…

Our analysis is one of the 1st 2 eval D-ER treatment patterns, budget impact, & HRU of #multiplesclerosis patients. https://t.co/DUHqP1a3MT

Patients who used D-ER had fewer trips to the doctor for walking-related issues. https://t.co/DUHqP1a3MT #multiplesclerosis

We evaluated real-world healthcare resource utilization associated with D-ER use. https://t.co/DUHqP1a3MT #multiplesclerosis

We evaluated real-world budget impact associated with D-ER use. https://t.co/DUHqP1a3MT #multiplesclerosis

We evaluated real-world treatment patterns associated with D-ER use. https://t.co/DUHqP1a3MT #multiplesclerosis

RT @OhioHealthMS: Treatment patterns & health care resource utilization associated with Ampyra: retrospective claims database analysis http…

Treatment patterns & health care resource utilization associated with Ampyra: retrospective claims database analysis https://t.co/dzyP4uvRFS

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple… https://t.co/oWFhRPlxGI

Dalfampridine-ER utilization in MS https://t.co/bcJdrm77UX